Bridgeway Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bridgeway Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,300	Closed	-$471K	–	1322
2019 Q1	$471K	Buy	+5,300	New	+$491K	0.01%	1040
2015 Q4	–	Sell	-61,100	Closed	-$6.43M	–	1440
2015 Q3	$6.43M	Sell	61,100 -3,800	-6%	-$508K	0.13%	177
2015 Q2	$8.88M	Buy	64,900 +39,300	+154%	+$4.87M	0.17%	142
2015 Q1	$3.19M	Buy	+25,600	New	+$2.71M	0.07%	349

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bridgeway Capital Management's BMRN Position: Q2 2019 in Review

Bridgeway Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 5,300 shares — an estimated $471K sold.

Bridgeway Capital Management first reported a position in BMRN in Q1 2015 and held it in 4 quarters. The position peaked at $8.88M in Q2 2015. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Bridgeway Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 5,300 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $471K.
Bridgeway Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 4 quarters.
Bridgeway Capital Management's BioMarin Pharmaceuticals position peaked at $8.88M in Q2 2015.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.